A Boston biotech launched last month with $93 million in hand and a bet that no one has figured out how to fix retinal disease properly. Memento Medicines announced the close of its Series A on June 18, 2026, co-led by Forbion, RA Capital Management, and Avego BioScience Capital, with a single mechanistic insight: retinal tissue does not just need less VEGF, it needs a blood vessel system that can hold itself together. The company is advancing a bispecific antibody that does both at once. It agonizes Tie2, an endothelial receptor that stabilizes the retinal vasculature. It also inhibits VEGF, the growth factor that drives the pathological leakage and neovascularization at the heart of wet age-related macular degeneration and diabetic macular edema. No approved therapy does both simultaneously.
That dual mechanism is the entire story. Ranibizumab and aflibercept suppress VEGF signaling or sequester the molecule itself. They work. Millions of patients have stable or improved vision because of them. Faricimab, however, targets two distinct pathways—VEGF-A and Ang-2—making it the first FDA-approved bispecific antibody for ophthalmic use and demonstrating that dual-target mechanisms have entered the retinal therapeutic landscape. But most existing therapies work on a single target, and retinal vasculature is not a single-target problem. Endothelial cells lining the blood vessels depend on Tie2 signaling to maintain adherens junctions, the cellular glue that keeps fluid from leaking out. When Tie2 signaling drops and VEGF surges simultaneously, the vessels become unstable. Existing therapies address the surge without restoring the stabilizer. Memento's insight is that a molecule that pushes Tie2 while pulling VEGF addresses both sides of the dysfunction in parallel.
The $93 million raise at company formation is not a market-validation round, it is a bet that Memento has preclinical or early clinical data strong enough to justify launching a company on a single mechanism in the most crowded therapeutic space in ophthalmology. Forbion, a longtime venture investor in therapeutic biologics, leading a co-investment on a Series A for an anti-VEGF variant in 2026 signals that the data exceeded the noise floor. Forbion does not write nine-figure checks for mechanistic iterations on mature market categories without seeing something materially differentiated in the bench work. Whether that translates to human efficacy is an open question, but the financing size and investor pedigree suggest Memento's team has shown enough in vitro and in vivo data to move IND development forward at speed.
For context on the broader market moment: Ray Therapeutics closed a $125 million Series B in April 2026 and secured an FDA Regenerative Medicine Advanced Therapy designation for RTx-015, its vision restoration candidate for retinitis pigmentosa, on April 1, 2026. Unity Biotechnology's UBX1325, a senolytic therapy for diabetic macular edema, demonstrated visual acuity gains exceeding five letters and non-inferiority to anti-VEGF at nine of ten timepoints in a Phase 2b trial through 36 weeks. The retinal space is not dormant, but it is not flooded with structurally novel mechanisms either. Memento arrives into a market where the incumbents are potent and entrenched, and where any new entrant must prove not just efficacy but superiority.
The critical tests ahead are surgical in their specificity. First: does the bispecific antibody maintain safety and tolerability in Phase 1 human dosing, a question that matters because Tie2 agonism is a less-explored mechanism in the retina, and off-target effects could eliminate the theoretical advantage? Second: what is the IND pathway timeline, and will the FDA accept a non-inferiority design against aflibercept, or will Memento need to prove superiority? Third, and most consequential: in a Phase 2b trial, does the dual mechanism reduce relapse rates or injection frequency versus current standard-of-care anti-VEGF therapy, the only outcome that would displace the incumbents from first-line use. If Memento delivers on any one of those, the retinal market shifts. If it stumbles on all three, it becomes a cautionary note on mechanistic novelty without clinical differentiation.